Adaptive Research News Today

Adaptive Research Inc.'s Deepak Behera, MD and Melissa Andrews make the case for community trial sites as the go-to source for ensuring more...

Half Yearly Report - 31 December 2023 Kazia Therapeutics Limited ...

Operator: Good afternoon, and welcome to Oncolytics Biotechs Fourth Quarter and Full Year 2023 Conference Call. All participants are now in a listen-only mode.

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcript March 9, 2024 Oncolytics Biotech Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to Oncolytics Biotech’s Fourth Quarter and Full Year 2023 Conference Call. All participants […]

/PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), a leading patient advocacy organization dedicated to fighting the worlds toughest cancer, in...

GBM AGILE Adaptive Platform Trial Recruiting in Australia

VAL-083 did not improve efficacy compared with standard-of-care approaches in patients with glioblastoma.

LARKSPUR, Calif. & PITTSBURGH--(BUSINESS WIRE)--Oct 25, 2023--

Simvastatin, a widely available and inexpensive drug that is included on the WHO list of essential medicines, was shown to have a high probability (96%) of improving outcomes (a combination of survival and length of time patients need support in an intensive care unit) when started as a treatment for critically ill patients with COVID-19, and a 92% chance of improving survival at 3 months.

Two randomized clinical trials were harmonized to compare the effect of vitamin C vs control on outcomes in hospitalized patients with COVID-19 who were critica